CARB-X: Combatting Antibiotic Resistance Bacteria


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Their projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $198.46 million in 59 projects around the world. Visit the CARB-X website to learn more.






Due to the Covid-19 crisis, the ICARe course has been canceled for 2020 and will resume again in 2021. 

white-logos.png
  • LinkedIn
  • Facebook
  • Twitter

Contact us at icarecourse@gmail.com.

© 2020 INTERDISCIPLINARY COURSE ON

ANTIBIOTICS AND RESISTANCE (ICARE)